Sorted By Test Name - Mayo Medical Laboratories

RNP
81357
FROPI
57171
Clinical References: 1. Koenig M, Dieude M, Senecal, J-L: Predictive value of antinuclear
antibodies: The lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008;7(8):588-593 2.
Wollheim FA: Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 2005
Oct;44(10):1212-1216 3. Cavazzana I, Ceribelli A, Paolo A, et al: Anti-RNA polymerase III antibodies: A
marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev
2009;8(7):580-584 4. Kuwana M, Kimura K, Kawakami Y: Identification of an immunodominant epitope
on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked
immunosorbent assay. Arthritis Rheum 2002 Oct;46(10):2742-2747
RNP Antibodies, IgG, Serum
Clinical Information: RNP (also called nRNP and U1RNP) is a small nuclear ribonucleoprotein that
contains 3 protein autoantigens (called A, C, and 68 kD). Sera that contain RNP antibodies react
predominately with the A and 68 kD autoantigens. Antibodies to RNP occur in approximately 50% of
patients with lupus erythematosus (LE) and in patients with other connective tissue diseases, notably
mixed connective tissue disease (MCTD). MCTD is characterized by high levels of RNP antibodies
without detectable Sm or double-stranded DNA (dsDNA) antibodies. MCTD resembles LE but is not
accompanied by renal involvement.(1,2) RNP is 1 of 4 autoantigens commonly referred to as extractable
nuclear antigens (ENAs). The other ENAs are SS-A/Ro, SS-B/La, and Sm. Each ENA is composed of 1
or more proteins associated with small nuclear RNA species (snRNP) ranging in size from 80 to
approximately 350 nucleotides. Antibodies to ENAs are common in patients with connective tissue
diseases (systemic rheumatic diseases) including LE, MCTD, Sjogren's syndrome, scleroderma (systemic
sclerosis), and polymyositis/dermatomyositis. See Connective Tissue Disease Cascade (CTDC) in Special
Instructions and Optimized Laboratory Testing for Connective Tissue Diseases in Primary Care: The
Mayo Connective Tissue Diseases Cascade in Publications.
Useful For: Evaluating patients with signs and symptoms of a connective tissue disease in whom the
test for antinuclear antibodies is positive
Interpretation: A positive result for RNP antibodies is consistent with a connective tissue disease.
Although strongly associated with connective tissue diseases, RNP antibodies are not considered a
"marker" for any particular disease except in the following situation: when found in isolation (ie, dsDNA
antibodies and Sm antibodies are not detectable), a positive result for RNP antibodies is consistent with
the diagnosis of mixed connective tissue disease.
Reference Values:
or =1.0 U (positive)
Reference values apply to all ages.
Clinical References: 1. Homburger H, Larsen S: Detection of specific antibodies. In Clinical
Immunology: Principles and Practice. 1st edition. Edited by R Rich, T Fleisher, B Schwartz, et al. St.
Louis, Mosby-Year Book, 1996, pp 2096-2109 2. Kotzin B, West S: Systemic lupus erythematosus. In
Clinical Immunology Principles and Practice. 2nd edition. Edited by R Rich, T Fleisher, W Shearer, et al.
St. Louis, Mosby-Year Book, 2001, pp 60.1-60.24
Ropivacaine, Serum/Plasma
Reference Values:
Following epidural administration 10 mg/hr, 20 mg/hr
and 30 mg/hr, mean plasma concentration of 0.39, 0.88,
1.19 mcg/mL at 21 hours respectively.
Bolus I.V. administration 84 mg/70 kg and 131 mg/70 kg,
peak plasma concentrations of 1.1 and 1.7 mcg/mL at
2 minutes respectively.
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1547